deltatrials
Completed NA INTERVENTIONAL 1-arm NCT00445744

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.

Sponsor: Fred Hutchinson Cancer Center

Conditions Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myeloid Leukemia in Remission Childhood Acute Myeloid Leukemia in Remission Childhood Myelodysplastic Syndromes Essential Thrombocythemia Myelodysplastic Syndrome With Isolated Del(5q) Polycythemia Vera Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Secondary Myelofibrosis Untreated Adult Acute Myeloid Leukemia Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies de Novo Myelodysplastic Syndromes
Interventions allogeneic hematopoietic stem cell transplantation busulfan cyclophosphamide cytogenetic analysis flow cytometry methotrexate peripheral blood stem cell transplantation pharmacogenomic studies pharmacological study tacrolimus
Updated 10 times since 2017 Last updated: Dec 1, 2017 Started: Dec 31, 2006 Primary completion: Jun 30, 2011 Completion: Jun 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Del(5q), this trial is completed. The trial is conducted by Fred Hutchinson Cancer Center and has accumulated 10 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshotCompleted~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~May 2022 · 16 months · monthly snapshotCompleted~May 2022 – ~Dec 2022 · 7 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2023 — Jul 2024 [monthly]

    Completed NA

  4. Dec 2022 — Jan 2023 [monthly]

    Completed NA

  5. May 2022 — Dec 2022 [monthly]

    Completed NA

▶ Show 5 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed NA

  2. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  3. Jan 2018 — Jun 2018 [monthly]

    Completed NA

  4. Feb 2017 — Jan 2018 [monthly]

    Completed NA

  5. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations